BIO-B — BIO-RAD LABORATORIES, INC.

NYSE · Unknown · Unknown · CIK 12208 ·
Last close
$365.08
Market Cap
$1.85B
52W High
$365.08
52W Low
$267.43
ADV30
10
Next earnings
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 651,000,000 345,800,000 72,600,000 371,400,000 10,252,000,000 517,000,000 3,078,100,000
Mar 2026 592,100,000 309,400,000 34,100,000 -527,100,000 9,790,000,000 507,200,000 2,938,700,000
Dec 2025 693,200,000 345,200,000 53,900,000 720,000,000 10,576,500,000 529,800,000 3,122,900,000
Sep 2025 653,000,000 343,400,000 63,900,000 -341,900,000 9,696,400,000 395,800,000 2,959,600,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$492,600,000
Investing CF
$-237,100,000
Financing CF
$-120,800,000
CapEx
$-139,500,000
Dividends Paid
Buybacks
$-132,700,000
EPS Diluted TTM
$32.62
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$8,020,600,000
Inventory
$780,600,000
Receivables
$441,800,000
ST Investments
$1,101,500,000
EBIT TTM
$399,200,000
Pretax Income TTM
$350,400,000
Interest Exp TTM
$48,800,000
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,589,299,968
EBITDA
$441,000,000
Free Cash Flow
$283,187,488
Enterprise Value
$9,513,473,024
Total Cash
$1,618,499,968
Total Debt
$1,370,400,000
Shares Out
5,061,038
Trailing EPS
$8.21
Book Value
$268.30
ROE
3.1%
ROA
1.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,583,200,000 218,600,000 759,900,000 10,576,500,000 3,122,900,000 532,200,000
Dec 2024 2,566,500,000 269,000,000 -1,844,200,000 9,364,100,000 2,794,800,000 455,200,000
Dec 2023 2,671,200,000 337,800,000 -637,300,000 12,299,100,000 3,557,900,000 374,900,000
Dec 2022 2,802,200,000 475,100,000 -3,627,500,000 13,501,666,000 3,886,414,000 194,400,000

TTM Snapshot

Revenues TTM
$2,563,648,000
NetIncome TTM
$1,518,914,000
OpCashFlow TTM
$0
Assets (Latest)
$9,364,100,000
Forward EPS

Peers — same industry

TickerNameMarket CapLastDaily %
USA LIBERTY ALL STAR EQUITY FUND $1.85B $6.00
ETG Eaton Vance Tax-Advantaged Global Dividend Income Fund $1.83B $24.03
NAC Nuveen California Quality Municipal Income Fund $1.83B $11.71
STRA Strategic Education, Inc. $1.87B $84.00
NUV NUVEEN MUNICIPAL VALUE FUND INC $1.88B $8.95

News headlines (Yahoo Finance, 1h cache)

Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
2026-08-21 14:31 · Yahoo
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?
2026-08-14 00:13 · Yahoo
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
2026-08-10 20:05 · Yahoo
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock
2026-08-10 13:15 · Yahoo
Bio Rad Laboratories (BIO) Earnings And Guidance Put Fair Value Back In Focus
2026-08-09 22:16 · Yahoo
Bio-Rad Laboratories, Inc. Q2 2026 Earnings Call Summary
2026-08-05 12:30 · Yahoo
Bio-Rad Laboratories Inc (BIO) (Q2 2026) Earnings Call Highlights: Digital PCR Surges 20%+ as ...
2026-08-05 05:02 · Yahoo
Bio-Rad Laboratories Q2 Earnings Call Highlights
2026-08-05 04:03 · Yahoo
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
2026-07-23 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.